#Protein design
2 tools curated for you
Complete antibody design campaigns 56 times faster than working manually, using AI that autonomously generates novel antibodies from text prompts. Run multiple antibody design campaigns simultaneously, with a force multiplier that lets a single researcher expand the scale of therapeutic exploration. Generate novel, lab-confirmed binders with single-digit nanomolar affinities, validated across several campaign types for reliable drug discovery results. Skip coding entirely with a complete no-coding drug design workflow fully embedded in the Latent Labs platform. Apply expert-level antibody design reasoning with built-in access to bioinformatics tools, biological databases, and external publications. Choose full end-to-end autonomy or a human-in-the-loop approach with interactive review of progress summaries and recommended next steps. Audit every design decision through logged AI reasoning, delivering full transparency and interpretability at each stage of protein design.
Generate high-affinity protein binders directly from a target sequence with Latent-X generative design, eliminating months of manual candidate screening Advance antibodies, macrocycles, and mini-proteins through one unified AI protein design platform instead of running separate discovery pipelines for each modality Move into wet-lab testing with candidates that already demonstrate picomolar binding affinity and drug-like properties, reducing costly synthesis cycles on weak hits Trust results validated experimentally across multiple targets including IL-6, PD-L1, MMP2, SARS-CoV-2 RBD, MCL-1, and MDM2 rather than relying on in silico predictions alone Compress the traditional long wet-lab drug discovery cycle into fast generative design of developable candidates for biotech and pharma research teams Review peer-style technical reports on arXiv for the Latent-X and Latent-Y models to evaluate methodology before committing to a discovery campaign